지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.12
- 수록면
- 273 - 278 (6page)
이용수
초록· 키워드
오류제보하기
Objectives：We retrospectively investigated the efficacy and tolerability of risperidone monotherapy in subjects with autism spectrum disorder (ASD). In addition, we did mixed effect model analysis of the effects of risperidone in patients with ASDs naturalistically treated in a routine clinical setting to determine whether the clinical effects were maintained and the side effects were tolerable.
Methods：This retrospective study assessed children and adolescents with ASD, who were on risperidone monotherapy from July 2010 to July 2011 at the Child and Adolescent ASD Clinic at Seoul National Hospital. Outcome measures included the Clinical Global Impression-Severity of Illness (CGI-S) and the CGI-Improvement (CGI-I) scales along with other clinical indices: dosage, target symptoms, and side effects.
Results：The mean dose of risperidone in 47 children and adolescents with ASD (40 males, 7 females; age range 5–19 years) who were on risperidone monotherapy was 1.6±0.8 mg/day, and the mean duration of the treatment period was 20.2±17.3 months. Aggressive behavior, stereotypic behavior, irritability, and self-injurious behavior were the most frequent target symptoms of risperidone. The most common side effects were weight gain followed by somnolence and extrapyramidal symptoms. In a mixed effects model analysis of CGI-I scores, the mean CGI-I score at the 1 month follow-up was significantly different from the mean CGI-I score of the 3-month follow-up (p=.046), and the CGI-I scores were equally maintained over 3 to 48 months [F(6, 28.9)=4.393, p=.003]. Of the 47 patients, 33 patients (70.2%) were identified as the response group, showing an end point CGI-I rating of 3 or under and having continued risperidone treatment for at least 6 months. The baseline CGI-S score showed significant association with clinical response to risperidone (p=.005), the mean baseline CGI-S was higher in the response group compared to the non-response group.
Conclusion：In this study, clinical improvement of risperidone stabilized around 3 months and was equally maintained up to 48 months with tolerable side effects, supporting maintenance of risperidone treatment in children and adolescents with ASDs.
Methods：This retrospective study assessed children and adolescents with ASD, who were on risperidone monotherapy from July 2010 to July 2011 at the Child and Adolescent ASD Clinic at Seoul National Hospital. Outcome measures included the Clinical Global Impression-Severity of Illness (CGI-S) and the CGI-Improvement (CGI-I) scales along with other clinical indices: dosage, target symptoms, and side effects.
Results：The mean dose of risperidone in 47 children and adolescents with ASD (40 males, 7 females; age range 5–19 years) who were on risperidone monotherapy was 1.6±0.8 mg/day, and the mean duration of the treatment period was 20.2±17.3 months. Aggressive behavior, stereotypic behavior, irritability, and self-injurious behavior were the most frequent target symptoms of risperidone. The most common side effects were weight gain followed by somnolence and extrapyramidal symptoms. In a mixed effects model analysis of CGI-I scores, the mean CGI-I score at the 1 month follow-up was significantly different from the mean CGI-I score of the 3-month follow-up (p=.046), and the CGI-I scores were equally maintained over 3 to 48 months [F(6, 28.9)=4.393, p=.003]. Of the 47 patients, 33 patients (70.2%) were identified as the response group, showing an end point CGI-I rating of 3 or under and having continued risperidone treatment for at least 6 months. The baseline CGI-S score showed significant association with clinical response to risperidone (p=.005), the mean baseline CGI-S was higher in the response group compared to the non-response group.
Conclusion：In this study, clinical improvement of risperidone stabilized around 3 months and was equally maintained up to 48 months with tolerable side effects, supporting maintenance of risperidone treatment in children and adolescents with ASDs.
목차
Introduction
Methods
Results
Discussion
Conclusion
References
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Early Diagnosis of Autism Spectrum Disorder
대한소아청소년정신의학회 학술대회논문집
2018 .05
-
An update on the cause and treatment of sleep disturbance in children and adolescents with autism spectrum disorder
Journal of Yeungnam Medical Science
2021 .10
-
한방치료로 호전된 자폐스펙트럼장애 1례 보고
대한한방소아과학회지
2018 .01
-
자폐 스펙트럼 장애 환아 1례에 대한 증례 보고
대한한방소아과학회지
2017 .01
-
청소년 자폐스펙트럼장애에서 사회기술훈련의 효과에 미치는 우울, 불안 증상의 영향
대한불안의학회지
2018 .01
-
Loss of Acquired Skills: Regression in Young Children With Autism Spectrum Disorders
소아청소년정신의학
2023 .01
-
자폐스펙트럼 장애 아동에게 목표관리 훈련이 양측활동에 미치는 영향: 예비연구
한국신경인지재활치료학회지
2018 .01
-
Managing Aggressive Behavior in Adolescents With Autism Spectrum Disorder: Pharmacological and Non-Pharmacological Approaches
소아청소년정신의학
2024 .10
-
Diagnosis and evaluation criteria for autism spectrum disorders in the field of animal assisted intervention
한국실험동물학회 학술발표대회 논문집
2021 .07
-
자폐스펙트럼장애 아동들의 효과적인 조기 중재에 대한 체계적 고찰
재활치료과학
2018 .01
-
Recent update of autism spectrum disorders
Korean journal of pediatrics
2015 .01
-
공격적 문제행동을 보이는 자폐스펙트럼장애 아동청소년의 임상적 특징 : 예비연구
소아청소년정신의학
2017 .10
-
Comparison of the Autism Diagnostic Observation Schedule and Childhood Autism Rating Scale in the Diagnosis of Autism Spectrum Disorder : A Preliminary Study
소아청소년정신의학
2018 .10
-
Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial
Clinical Psychopharmacology and Neuroscience
2019 .01
-
동물매개치료가 자폐스펙트럼장애아동의 대인관계, 언어 및 행동에 미치는 사례연구
한국보건기초의학회지
2020 .01
-
Review of Early Intervention for Children with Autism Spectrum Disorder: Focused on Randomized Controlled Trials
소아청소년정신의학
2019 .10
-
A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder
Clinical Psychopharmacology and Neuroscience
2017 .01
-
Virtual Reality (VR) Research for Children with Autism Spectrum Disorder (ASD)
대한소아청소년정신의학회 학술대회논문집
2017 .05
-
Vitamin D Supplementation is Beneficial for Children with Autism Spectrum Disorder: A Meta-analysis
Clinical Psychopharmacology and Neuroscience
2020 .01
-
Effect of AVATA Cure Digital Therapeutics for Improving Social Communication Skills in Children with Autism Spectrum Disorder: Pilot Clinical Trial
대한소아청소년정신의학회 학술대회논문집
2024 .11
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-516-002219467